# Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

> **NCT00482846** · PHASE1 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 38 (actual)

## Conditions studied

- Mucositis
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Palifermin
- **DRUG:** melphalan
- **OTHER:** questionnaire administration
- **PROCEDURE:** autologous peripheral blood stem cell transplantation
- **OTHER:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00482846
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2011-10
- **Final completion:** 2012-09
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482846, "Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00482846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*